103 related articles for article (PubMed ID: 38752390)
1. PAPP-A as a Potential Target in Thyroid Eye Disease.
Conover CA; Bale LK; Stan MN
J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38752390
[TBL] [Abstract][Full Text] [Related]
2. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L; Smith TJ; Janssen JAMJL
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
[TBL] [Abstract][Full Text] [Related]
3. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
Wang R; Song D; Zhong Y; Li H
BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter, Single-Blind, Case-Control, Immunohistochemical Study of Orbital Tissue in Thyroid Eye Disease.
Hai YP; Saeed MEM; Ponto KA; Elflein HM; Lee ACH; Fang S; Zhou H; Frommer L; Längericht J; Efferth T; Kahaly GJ
Thyroid; 2022 Dec; 32(12):1547-1558. PubMed ID: 36128805
[No Abstract] [Full Text] [Related]
5. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
[TBL] [Abstract][Full Text] [Related]
6. LncRNA LPAL2/miR-1287-5p/EGFR Axis Modulates TED-Derived Orbital Fibroblast Activation Through Cell Adhesion Factors.
Wang N; Hou SY; Qi X; Deng M; Cao JM; Tong BD; Xiong W
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2866-e2886. PubMed ID: 33877318
[TBL] [Abstract][Full Text] [Related]
7. Thyroid eye disease: From pathogenesis to targeted therapies.
Yoon JS; Kikkawa DO
Taiwan J Ophthalmol; 2022; 12(1):3-11. PubMed ID: 35399971
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
9. Updates on the understanding and management of thyroid eye disease.
Men CJ; Kossler AL; Wester ST
Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
[TBL] [Abstract][Full Text] [Related]
10. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
Neumann S; Krieger CC; Gershengorn MC
Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
[TBL] [Abstract][Full Text] [Related]
11. The pathophysiology of thyroid eye disease.
Shan SJ; Douglas RS
J Neuroophthalmol; 2014 Jun; 34(2):177-85. PubMed ID: 24821101
[TBL] [Abstract][Full Text] [Related]
12. TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.
Woeller CF; Roztocil E; Hammond C; Feldon SE
Invest Ophthalmol Vis Sci; 2019 Oct; 60(13):4336-4345. PubMed ID: 31622470
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy-associated plasma protein-A (PAPP-A) is a key component of an interactive cellular mechanism promoting pulmonary fibrosis.
Bale LK; Schafer MJ; Atkinson EJ; Le Brasseur NK; Haak AJ; Oxvig C; Conover CA
J Cell Physiol; 2022 Apr; 237(4):2220-2229. PubMed ID: 35098542
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
15. Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity.
Mikkelsen JH; Resch ZT; Kalra B; Savjani G; Kumar A; Conover CA; Oxvig C
Oncotarget; 2014 Feb; 5(4):1014-25. PubMed ID: 24572990
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy-Associated Plasma Protein A Induces Inflammatory Cytokine Expression by Activating IGF-I/PI3K/Akt Pathways.
Li W; Li H; Zhou L; Wang Z; Hua B
Mediators Inflamm; 2019; 2019():8436985. PubMed ID: 31582904
[TBL] [Abstract][Full Text] [Related]
17. Molecular regulation of the IGF-binding protein-4 protease system in human fibroblasts: identification of a novel inducible inhibitor.
Chen BK; Overgaard MT; Bale LK; Resch ZT; Christiansen M; Oxvig C; Conover CA
Endocrinology; 2002 Apr; 143(4):1199-205. PubMed ID: 11897673
[TBL] [Abstract][Full Text] [Related]
18. A New Era in the Treatment of Thyroid Eye Disease.
Patel A; Yang H; Douglas RS
Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.
Fernando R; Smith TJ
J Clin Endocrinol Metab; 2022 Sep; 107(10):e4037-e4047. PubMed ID: 35809263
[TBL] [Abstract][Full Text] [Related]
20. The miR-103a-3p/TGFBR3 axis regulates TGF-β-induced orbital fibroblast activation and fibrosis in thyroid-eye disease.
Xie B; Xiong W; Zhang F; Wang N; Luo Y; Chen Y; Cao J; Chen Z; Ma C; Chen H
Mol Cell Endocrinol; 2023 Jan; 559():111780. PubMed ID: 36179941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
